Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
NM-702 oral tablets are being developed for the treatment of Intermittent Claudication, a
primary early stage indication of peripheral arterial disease (PAD). This trial is designed
to assess the safety and efficacy of 4 mg and/or 8 mg NM-702 taken twice a day (BID) for 24
weeks to see if it improves peak walking time (PWT) more than placebo for the treatment of
Intermittent Claudication.